Purpose There is no effective therapy for patients with advanced medullary thyroid
carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular …

Abstract On April 6, 2011, the US Food and Drug Administration approved vandetanib
(Caprelsa tablets; AstraZeneca Pharmaceuticals LP) for the treatment of symptomatic or …

6018 Background: Medullary thyroid cancer (MTC) is the most common cause of death in
patients with hereditary syndromes caused by activating mutations in the RET …

Purpose There is no effective therapy for patients with distant metastasis of medullary thyroid
carcinoma (MTC). Activating mutations in the RET proto-oncogene cause hereditary MTC …

Purpose: Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor
receptor-2 and epidermal growth factor receptor tyrosine kinases that also inhibits …

Abstract Vandetanib (ZD6474, Caprelsa, AstraZeneca), an oral small-molecule tyrosine
kinase inhibitor (TKI) that targets the rearranged during transfection receptor (RET), VEGF …

Background No effective standard treatment exists for patients with radioiodine-refractory,
advanced differentiated thyroid carcinoma. We aimed to assess efficacy and safety of …

Background: Management of patients with advanced medullary thyroid cancer (MTC)
remains a therapeutic challenge. The multi-tyrosine kinase inhibitors (TKIs) vandetanib and …

Vandetanib is an orally active antagonist of vascular endothelial growth factor (VEGF)
receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR or HER1 or ErbB1) and RET …

Purpose: Medullary thyroid carcinoma (MTC) is a manifestation of multiple endocrine
neoplasia type 2 (MEN2) syndromes caused by germline, activating mutations in the RET …